Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 96 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cervical Intraepithelial Clear all

Conditions: Cervical Cancer, Precancerous Condition
Interventions: folic acid, placebo; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Barrett's Esophagus, Esophageal Intraepithelial Neoplasia
Interventions: endomicroscopy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Precancerous Condition
Interventions: Colposcopic biopsy, Light-Scattering Spectroscopy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,070 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Papillomavirus Infections
Interventions: 851B; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 88
States / cities: Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more

Conditions: Cervical Cancer
Interventions: Reflectance Confocal Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Cervical Cancer
Interventions: Fluorescence Spectroscopy, Colposcopy, LEEP Procedure; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Cervical Intraepithelial Neoplasia
Interventions: ADXS11-001 (Lm-LLO-E7), Placebo Control; Biological · Drug
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 15
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more

Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasia II, Cervical Intraepithelial Neoplasia III
Interventions: Not listed
Lead sponsor: Onconix, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Neoplasm Cervix
Interventions: Curcumin C3 Complex, Placebo; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 21 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Cervical Intraepithelial Neoplasia
Interventions: Placebo, RO5217790; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Squamous Intraepithelial Neoplasia, Early Invasive Cervical Adenocarcinoma, Early Invasive Cervical Squamous Cell Carcinoma, High Grade Cervical Squamous Intraepithelial Neoplasia, High Grade Vaginal Intraepithelial Neoplasia, Low Grade Vaginal Intraepithelial Neoplasia, Stage I Cervical Cancer AJCC v8, Stage I Vaginal Cancer AJCC v8, Stage I Vulvar Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Vaginal Cancer AJCC v8, Stage IA Vulvar Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Vaginal Cancer AJCC v8, Stage IB Vulvar Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage II Vulvar Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Adenocarcinoma, Vulvar Adenocarcinoma, Vulvar High Grade Squamous Intraepithelial Lesion, Vulvar Intraepithelial Neoplasia, Vulvar Squamous Cell Carcinoma, Vulvar Squamous Intraepithelial Lesion
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 2
States / cities: Houston, Texas

Conditions: High-risk HPV Infection and Biopsy-proven CIN1
Interventions: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7; Biological
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Port Jefferson, New York • The Bronx, New York

Conditions: Cervical Cancer, Precancerous Condition
Interventions: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasias, Digital Colposcopy, Precancerous Cervical Lesions
Interventions: Diagnostic imaging aid for one-visit management of cervical lesions; Device
Lead sponsor: Brookdale University Hospital Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Head and Neck Cancer
Interventions: fenretinide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 15
States / cities: Tucson, Arizona • Kansas City, Kansas • Lexington, Kentucky + 7 more

Conditions: Sexually Transmitted Infections, HIV Infections
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Cervical Intraepithelial Neoplasia
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 26 Years to 65 Years · Female only
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Precancerous Condition
Interventions: HspE7; Biological
Lead sponsor: Dana-Farber/Brigham and Women's Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Placebo, Electroporation (EP); Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 22
States / cities: Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Papillomavirus Infections
Interventions: VGX-3100; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Precancerous Condition
Interventions: imiquimod, Ablative or excisional therapy; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more

Conditions: Cervical Cancer
Interventions: Loop Electrosurgical Excision Procedure (LEEP); Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Gastro-Intestinal Intraepithelial Neoplasia
Interventions: Fluorouracil injection, Xeloda; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 6 more

Conditions: Cervical Intraepithelial Neoplasia
Interventions: Not listed
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Augusta, Georgia

Search by objective public record fields.

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study)

Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Reflectance Confocal Imaging in Cervical Cancer Patients

Spectroscopy Versus Standard Care in Cervical Cancer Patients

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer

Topical Curcumin for HPV Related Cervical Disease

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Diagnostic Imaging Aid for Management of Cervical Lesions

SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

Sexually Transmitted Infections Among African American Women Who Have Sex With Women

Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta

SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Clinical Evaluation of Polarized Light Assisted Colposcopy